Navan Technologies, Inc., South San Francisco, CA-based biotechnology company, closed a seed investment round of undisclosed amount.
The round was led by Amgen Ventures, High-Tech Gründerfonds (HTGF), Hemi Ventures, and other institutional and private investors. Based on technology exclusively licensed from Stanford University, Navan is also supported by a National Science Foundation STTR Phase II award and is a resident company at JLABS @ SSF located at Oyster Point in South San Francisco, CA.
The company intends to use the funds to:
– further platform development,
– scale-up production capabilities, and
– facilitate strategic collaborations and partnerships to accelerate the development of therapeutics programs.
Led by Michael J. Nowak, Ph.D., President and Chief Executive Officer, Navan Technologies is a biotechnology company enabling the development of next generation cell and gene therapies. A non-viral physical delivery technology, NanoStraws, provides direct access to the cytosol of a cell and hence enable the delivery of Any Cargo into Any Cell in a non-perturbative manner. Cell transformation via NanoStraws aims to reduce the complexity, cost and technical challenges involved in cell therapy manufacturing, allowing the company to actively pursue the development of innovative therapies in a broad range of indications with its strategic collaborators and partners.